| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
1 Institut National de la Sante et de la Recherche Medicale, U 45/IFR62; 2 IFR 128 BioSciences Lyon-Gerland, Institut de Biologie et Chimie des Protéines, Centre National de la Recherche Scientifique UMR 5086; and 3 Université Claude Bernard Lyon I, Lyon, France
Requests for reprints: Patricia Rousselle, Institut de Biologie et Chimie des Protéines, Centre National de la Recherche Scientifique, Université Lyon 1, 7 passage du Vercors, 69367 Lyon, France. Phone: 33-04-72-72-26-39; Fax: 33-04-72-72-26-02; E-mail: p.rousselle{at}ibcp.fr.
| Abstract |
|---|
|
|
|---|
3, ß3, and
2 chains, is an important component of epithelial basement membranes where it induces firm adhesion and hemidesmosome formation. In this study, we show that LN5 and MMP7 are coexpressed in HT29 cells as well as in HT29 xenograft tumors and human colorectal adenocarcinomas. We provide evidence that human LN5 is a ligand for MMP7 and that a specific cleavage occurs in its ß3 chain, giving rise to a carboxyl-terminal ß3 chain fragment of 90 kDa. We have identified the MMP7 cleavage site at position Ala515-Ile516 in the ß3 chain. Videomicroscopic analysis of HT29 cells plated on LN5 substrates reveals that the MMP7-processed LN5 significantly enhances cell motility. Moreover, the delayed migration of HT29 cells obtained after specific inhibition of MMP7 reinforces the hypothesis supporting its involvement in cell migration. Altogether, our results show that MMP7 is likely to play a crucial role in the regulation of carcinoma cell migration by targeting specific proteolytic processing of the LN5 ß3 chain. (Cancer Res 2006; 66(23): 11228-37) | Introduction |
|---|
|
|
|---|
80 amino acids, a catalytic domain of
170 amino acids, a linker peptide called the "hinge region," and a hemopexin domain of
200 amino acids (1).
Matrilysin-1 (MMP7), which lacks the hemopexin domain, is one of the most important member of this family and is mostly expressed in the cells of gastrointestinal, breast, and lung carcinomas (2). It has been shown to play important roles in the regulation of several biochemical processes, such as the activation-degradation of various proteins such as pro-
-defensin, Fas-ligand, pro-tumor necrosis factor
, and E-cadherin (1). Otherwise, MMP7 is known for its role on ECM degradation. It has a broad substrate specificity against most ECM components (3) and correlates in colon carcinoma with distant and lymph node metastasis (4, 5).
One of the main components of epithelial basement membranes is the laminin isoform laminin-5/laminin-332 (LN5; refs. 6, 7). This trimeric molecule formed by the association of the
3, ß3, and
2 chains is known for its role in promoting cell migration, notably those with malignant characteristics, and may act as a ligand for invasive carcinoma cells (8). Neoexpression of LN5 has also been associated with the proliferating activity of carcinoma cells. Moreover, this expression is often located in invasive areas of carcinomas (9). For example, in vivo observations have reported the overexpression of LN5 in budding cells, which then escape from the tumor as part of the metastatic cascade (10). Little is known about the mechanism by which LN5 plays a role in cell invasion but numerous earlier studies have shown that limited proteolytic processing of specific LN5 subunits alter protein structure and thereby modulates its functions, e.g., in cell motility (11). Specific cleavage of the LN5
2 chain by several members of the MMP family has been proposed to favor cell migration (12), among which the cleavage of the
2 chain by both MMP2 and membrane type-1 (MT1)-MMP (13). These findings were recently challenged by a study showing that the
2 chain in LN5 of human origin was insensitive to the MMP2 activity (14). More recently, the cleavage of the ß3 chain of human LN5 by MT1-MMP was reported to enhance the migration of prostate carcinoma cells (15).
It is now well established that MMP7 and LN5 have roles to play in cancer invasion; however, no direct link between these two partners has ever been shown. Although an indirect connection was proposed with a role for MMP7 in activating pro-MMP2 to MMP2, the latter leading to cleavage of the
2 chain of rat LN5 (13), the direct involvement of MMP7 in LN5 processing has never been reported.
In this study, we analyzed the expression of MMP7 and LN5 in the colon carcinoma cell line HT29 and found that these two antigens displayed a similar pattern in cells located at the edges of colonies. We further showed that incubation of MMP7 with human LN5 produced a 90 kDa fragment and we characterized the nature of this fragment as a ß3 chain product. We designed HT29 cell migration experiments on MMP7-cleaved LN5 and provided evidence that this cleavage led to enhancement of migratory behavior. Finally, we examined the expression of MMP7 and LN5 in HT29 cell xenografts and in human colonic adenocarcinomas.
| Materials and Methods |
|---|
|
|
|---|
3ß3
2 chains), monoclonal antibody (mAb) 6F12 (anti-ß3 chain), and mAb BM165 (anti-
3 chain) was described elsewhere (6, 17). The pAb PAB-G2 antibody was raised against a peptide corresponding to the amino-terminal extremity of the
2 chain. The mAb D4B5 (anti-
2 chain) was from Chemicon (Euromedex, Souffelweyersheim, France) and mAb kalinin B1 (against the carboxyl-terminal extremity of the ß3 chain) was from BD Biosciences (Le Pont-de-Claix, France). The rabbit anti-MMP7 pAb 8118, the anti-MMP7 mAb ID2, and the anti-MMP7 mAb 3322 (clone 176-5F12) against the peptide YSLFP, R78-82 were from Chemicon. Purification of human LN5 and cleavage of LN5 by MMP7. Mature human LN5 was purified as previously described (6, 18). Recombinantly expressed human MMP7 and human MMP2 (Chemicon) were used. One microgram of purified LN5 was mixed with 0.5, 0.7, or 1 µg of either activated MMP7 or MMP2 for 3 hours at 37°C in 50 mmol/L Tris (pH 7.4), 150 mmol/L NaCl, 10 mmol/L CaCl2 (final volume of 20 µL). Concentrations of enzymes were 25, 35, and 50 µg/mL, respectively. After incubation, the samples were prepared for electrophoresis in a 7.5% SDS-PAGE gel under reducing conditions. Proteins were transferred to nitrocellulose followed by immunodetection with Western Lightning Chemiluminescence Reagent Plus (Perkin-Elmer Life Science, Boston, MA).
Analytic methods. For amino-terminal amino acid sequencing, 5 µg LN5 were digested with 2 µg MMP7 as described above, and the resulting protein was subjected to electrophoresis in a 7.5% SDS-PAGE gel under reducing conditions. Proteins were electrotransferred onto polyvinylidene difluoride membrane (Problott, Applied Biosystems, Courtaboeuf, France) for 2 hours at 60 V in 10 mmol/L CAPS, 5% methanol (pH 11), then the band of interest was excised after brief staining with 0.1% Coomassie brilliant blue in 1% acetic acid (Sigma, Saint-Quentin Fallavier, France). Amino acid sequence analysis was done by automated Edman degradation using an Applied Biosystems 473A protein sequencer.
Tumor xenografting. HT29 cells (106), suspended in 100 µL PBS, were grafted onto 10 Wistar newborn rats (IFFA CREDO, Lyon, France) through a ventral s.c. injection. The rats were immunosuppressed by dorsal s.c. injections of 50 µL antithymocyte serum at days 0, 2, 7, and 14 after grafting (19) and maintained in a pathogen-free environment. Three weeks later, tumors were excised, frozen, and stored in liquid nitrogen. Tissue sections of 7-µm depth were fixed in acetone and stained with hematoxylin-safran for histologic analysis.
Human tissue specimen. Eight colorectal adenocarcinomas from patients who underwent surgery were retrieved from the Tumorothèque des Hospices Civils de Lyon, University of Lyon, Lyon, France. After surgery, tissues were immediately frozen in liquid nitrogen. Frozen sections were cut at a thickness of 7 µm and fixed in precooled acetone 10 minutes at +4°C. Tissue sections were stained with hematoxylin-safran for histologic analysis.
Immunohistochemistry. Fixed frozen tissue sections were rehydrated with 10% FCS in PBS. After washing, sections were incubated 45 minutes with the anti-LN5 antibodies (pAb L132 or mAb 6F12), washed in PBS, and incubated an additional 45 minutes with the anti-MMP7 antibodies (either mAb ID2 or pAb 8118). Cy3- and FITC-conjugated antibodies (Jackson, Beckman Coulter, Paris, France) were applied together for 30 minutes. Staining of the nuclei was done with a 15-minute incubation with a 0.5 µg/mL Hoechst stain solution (Sigma Immunochemicals, Dutscher, Brumath, France). Slides were observed with an Axioplan Zeiss microscope coupled to a Coolsnap Fx Camera (Roper Scientific, Evry, France).
HT29 cells were grown on coverslips. After washing, cells were fixed with 4% paraformaldehyde in PBS for 20 minutes, permeabilized with 0.1% Triton X-100 for 3 minutes, and rinsed with PBS. Cells were incubated with the anti-LN5 antibodies, washed in PBS, and incubated an additional 45 minutes with the anti-MMP7 antibodies (same as above). Alexa Fluor 488 and Alexa Fluor 546 antibodies were applied for 30 minutes. A 5-minute incubation with Syto 59 red allowed staining of nuclei. Cells were observed by laser scanning confocal microscopy (Zeiss LSM 510).
Protein detection by Western blotting. For LN5 and MMP7 detection, medium samples were prepared for electrophoresis in a 7.5% SDS-PAGE gel under reducing conditions. Proteins were transferred to nitrocellulose, followed by immunodetection by enhanced chemiluminescence (ECL). For MMP7 detection, nitrocellulose membranes were incubated for 1 hour at room temperature with primary antibodies, followed by biotinylated species-specific antibodies, washed, and incubated with peroxidase-streptavidin-biotin complexes (Amersham Pharmacia Biotech, Saclay, France). Detection was assessed by ECL.
Reverse-transcription PCR. Briefly, total RNA was extracted from cultured cells with TRIzol and were reverse-transcribed. cDNAs were amplified by PCR with previously published primers (20). ß-Actin was amplified as a reference gene. PCR gels (2% agarose stained with ethidium bromide) were digitized with the Image System (Quantum Appligene, Pleasanton, CA).
Wound-healing assay. Wound-healing assays were done using cultured cells. After confluence, a wound was made with a razor blade and the culture medium was replaced. The cells were allowed to heal for 10 days at 37°C in the presence of the MMP7 function neutralizing mAb 3322. A dish was fixed every day with 2% paraformaldehyde in PBS. The average extent of wound closure was quantified by multiple measurements of the width of the wound. Twenty-five measurements of two separate trials were made for all conditions. Ki67 labeling was done at each point to verify that the presence of tumor cells beyond the wound line had resulted from migration rather than proliferation processes.
Time-lapse videomicroscopy. Permanox Lab-tek chamber slides (Nalge Nunc International/Dutscher, Dutscher, Brumath, France) were coated overnight with LN5- or MMP7-cleaved LN5 at 4°C. After saturation with 1% bovine serum albumin, cultured HT29 cells suspended in DMEM containing 25 µg/mL cycloheximide were seeded at 8 x 103 per well. Cell migration was monitored at 37°C for 16 hours in a humidified atmosphere containing 5% CO2 using an Axiovert 100 M Zeiss microscope equipped with a Coolsnap Fx Camera (Roper Scientific). In each experiment and on each substrate, we analyzed movements of 100 cells using Metaview (Universal Imaging Corporation, Molecular Device, Roper Scientific). The rate of movement (µm/h) was calculated and P values were determined.
| Results |
|---|
|
|
|---|
3, ß3, and
2 chains) and MMP7 (Fig. 1A) revealed that, whereas LN5 was expressed in the entire colony, an intense expression of MMP7 was seen in cells located in the periphery of the colony. The superposition of both the LN5 and MMP7 staining revealed an obvious area of colocalization in and around the peripheral cells of the colony. To verify whether all LN5 subunits were expressed in a comparable pattern, similar experiments were done using antibodies against the
2 chain (Fig. 1B), the ß3 chain (Fig. 1C), or the
3 chain (Fig. 1D) of LN5. In these experiments, the detection of MMP7 was assessed concomitantly with either monoclonal (Fig. 1A and B) or polyclonal antibodies (Fig. 1C and D). In a manner comparable with the results obtained with staining of the entire LN5, each of the three LN5 subunits was expressed in all cells with increased intensity at the colony periphery. The staining of MMP7 was, as expected, identical to that described in Fig. 1A. Again, the superposition of the staining of each of the three LN5 subunits and that of MMP7 revealed an apparent peripheral ring-shaped area of colocalization identical to that described above. These data show that the three LN5 subunits
3, ß3, and
2 colocalize with MMP7 in these areas. Taken together, these data suggest that because all LN5 subunits were expressed in a similar pattern, the entire heterotrimeric LN5 is expressed in close proximity to MMP7 in specific areas of cultured HT29 cells. Most interestingly, as the cell clusters enlarge, only the peripheral cells express MMP7, suggesting that the cells at the interior of the cluster are no longer synthesizing this antigen. A similar LN5 pattern was previously described in cultured normal human keratinocytes in which only growing and migrating cells at colony peripheries were intensively expressing LN5 (6). As LN5 was expressed by HT29 cells, we next analyzed the molecular composition of the LN5 produced by these cells in comparison with LN5 purified from keratinocyte cultures (Fig. 2A
). As previously documented (21), and as shown in our electrophoresis analysis followed by Western blotting detection using antibodies specific for each of the three LN5 chains, the LN5 produced by HT29 cells is identical to the human LN5 isolated from the culture medium of normal keratinocytes (Fig. 2A).
|
|
MMP7 induces a specific cleavage in the ß3 chain of LN5. As both LN5 and MMP7 were coexpressed in HT29 cells, we analyzed whether LN5 could serve as a substrate for this enzyme and whether a proteolytic effect could be observed (Fig. 3
). For this, 1 µg purified human LN5 was incubated with amounts of human MMP7 varying from 0.5 to 1 µg for 3 hours at 37°C. As MMP2 was shown to process the
2 chain in LN5 of rat origin (13), but seemed to be inefficient with human LN5 (14), human MMP2 was used under the same conditions as MMP7 in our assay. After incubation, the products were analyzed by electrophoresis on 7.5% SDS-PAGE under reducing conditions, followed by Western blot analysis with the anti-LN5 pAb L132 (Fig. 3A). As expected, the pAb L132 detected the three chains of LN5 (
3, 165 kDa; ß2, 140 kDa;
2, 155 and 105 kDa) in the control lanes (lanes 1, 2, and 3), in which LN5 was incubated with the corresponding amounts of digestion buffer but lacking the enzymes. Although these bands were also detected in the samples in which LN5 was preincubated with either MMP7 (lanes 4, 5, and 6) or MMP2 (lanes 7, 8, and 9), an additional band of 90 kDa was detected in the samples corresponding to the MMP7-digested LN5 only (lanes 4, 5, and 6, asterisks). Moreover, this 90 kDa band was equivalent in the three samples corresponding to the three concentrations of MMP7. This band was absent in the LN5 control samples (lanes 1, 2, and 3) and in the samples containing the LN5 preincubated with MMP2 (lanes 7, 8, and 9). To reveal the identity of this LN5-MMP7 proteolytic product, Western blot experiments were conducted with several mAbs directed against the three chains of LN5 (data not shown). A mAb directed against the carboxyl-terminal extremity of the ß3 chain recognized specifically the 90 kDa band (Fig. 3B, lane 2) as well as the intact form of the ß3 chain (140 kDa). These results suggest that the 90 kDa fragment could arise from the ß3 chain cleavage and represent a portion corresponding to its carboxyl-terminal extremity. To verify this hypothesis and further check the identity of the 90 kDa fragment cleavage site, the amino acid sequence analysis of the 90 kDa fragment was done by automated Edman degradation. For this purpose, 5 µg human LN5 was digested with 2 µg MMP7, and the resulting protein was subjected to electrophoretic migration in a 7.5% SDS-PAGE, electrotransferred to an adequate membrane, and stained with Coomassie brilliant blue. The amino-terminal sequence of the 90 kDa band was determined to be IRQCPDRTY, which starts at the Ile516 of the laminin ß3 chain and confirmed the identity of the fragment as the carboxyl-terminal portion of the ß3 chain.
|
|
|
|
| Discussion |
|---|
|
|
|---|
Previous studies have reported the proteolytic action of some MMPs, such as MMP2 (13) and MT1-MMP (31), on the
2 chain of LN5, leading to the migration of tumor cells. Our immunohistochemical analysis conducted with the colon carcinoma cells HT29 revealed a coexpression of the three LN5 subunits with MMP7 exclusively, in and around cells, localized at the periphery of growing colonies, suggesting a coexpression of these antigens in dividing and/or migrating cells. Potential interactions between MMP7 and LN5 have not been fully studied, and only a few reports have thus far been reported. Salmela et al. (32) showed that the MMP7 mRNA and LN5
2 chain partly colocalized at the invasive border of Barrett's esophageal adenocarcinoma. A coexpression of MMP7 and of the LN5
2 chain was described in colorectal carcinomas (33). Here, we report that MMP7 and the ß3 chain in LN5 colocalize in HT29 cell xenografts and in human colorectal adenocarcinomas. Little is known about the role of LN5 in cell invasion; however, a specific cleavage of the
2 chain by several MMPs has been proposed to play a role in favoring tumor cell migration. Indeed, Pirilä et al. (12) showed a cleavage of the LN5
2 chain by MMP3, MMP12, MMP13, and MMP20, but not by MMP7. Based on the fact that MMP7 up-regulates MMP2 and other metalloproteinases, the observations of Salmela et al. (32) and Masaki et al. (33) may be explained by the cleavage of the
2 chain by metalloproteinases other than MMP7.
A specific and direct interaction between MMP7 and LN5 has never been shown before. Interestingly, Akimoto et al. (34) have often observed the coexpression of ß3 and
2 chains in tumor cells budding from the tumor nest at the invasive front of colorectal carcinomas, which was also observed by Sordat et al. (22), who considers that
2ß3 expression marks the transition from a stationary to an invading phenotype. The mechanism of the intracellular accumulation of
2ß3 in budding cells remains unknown. Thus, these observations strongly suggest that LN5
2 and ß3 chains are both important in the invasiveness of cancer cells and encouraged us to investigate a possible relation between MMP7 and LN5. Therefore, by searching for the ligand of MMP7 in colonic carcinomas, we found an interesting connection with LN5. In vitro incubation of human purified LN5 with recombinant MMP7 specifically produced a 90 kDa band that did not show in the MMP2-digested human LN5 control. Using an anti-ß3 mAb, we showed that this band was a part of the 140 kDa ß3 chain. Finally, the amino-terminal sequence determination of the 90 kDa MMP7 generated fragment revealed its identity as a ß3 chain portion. This is a novel and important finding where we show that MMP7 specifically cleaves LN5 in only one location without degrading the entire molecule. The cleavage occurred rapidly and required physiologic concentrations of MMP7. We provide the MMP7 cleavage site in the ß3 chain as being located at position Ala515-Ile516. To our knowledge, our study reports the identification of the first MMP7 cleavage site in a laminin and reinforces the hypothesis of a crucial role for MMP7 in biological events, such as cell migration and tumor invasion. Moreover, we provide evidence that the colon carcinoma HT29 cells plated on MMP7-cleaved LN5 migrated over longer distances with a mean speed of 28 µm/h compared with HT29 cells plated on control LN5, which moved around over shorter distances with speeds ranging from 0 to 15 µm/h. Most interestingly, the stable transfection and expression of the ß3 chain in prostate carcinoma cells increased their spreading and migration properties (35). The fact that the overexpressed ß3 chain was not found to assemble into a LN5 heterotrimer and that the overexpressing cells developed higher tumor growth capacity after injection in severe combined immunodeficient mice (35) suggests that a specific sequence within the free ß3 chain may become available and responsible for cellular interactions and signal transduction. This is further strengthened by a study showing that the up-regulation of a NH2 terminustruncated ß3 isoform in Ewing family tumors may favor the observed oncogenic phenotype (36). Together, these results suggest that the MMP7 cleavage of the ß3 chain may allow a partial dissociation of the LN5 heterotrimer followed by a possible release/exposure of an active fragment within the ß3 subunit. Moreover, as the ß3 chain interacts with the NC1 domain of collagen VII (37, 38) to promote cohesion of anchoring complexes, it is also conceivable that its cleavage could dissociate this interaction and favor the disassembly of anchoring structures.
Our findings are in agreement with recent studies showing that the MT1-MMP cleavage of the ß3 chain in LN5 also enhanced human prostate carcinoma cell migration (15). A ß3 chainderived 80 kDa fragment was also found in the culture medium of normal keratinocytes (38). Although the released 80 kDa fragments were shown to belong to the carboxyl-terminal portion of the ß3 chain (15), the cleavage sites remain unknown, raising the question whether these are different or identical to that of MMP7. Further studies will be dedicated to solve this question.
The role of MMP7 in tumor progression remains unclear. Our data, showing that a MMP7 function-blocking antibody was able to significantly delay the closure of a wound made in confluent HT29 cell layer, strongly suggests that MMP7 plays a role in cell migration. Altogether, our results show that MMP7 is likely to play a crucial role in the regulation of carcinoma cell migration by targeting specific proteolytic processing of the LN5 ß4 chain. Such results bring new evidence to the importance of relations between MMP and ECM components in cancer progression and give specific roles to MMP7 and LN5 interactions in the invasive process.
| Acknowledgments |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Prof. J.A. Chayvialle and Dr. P. Plaisancié for valuable discussions; the "Plateau Technique Imagerie Microscopie," Ecole Normale Supérieure de Lyon for providing the location of time-lapse videomicroscopy experiments; and Nicolas Gadot (Anipath, Lyon) and Florian Lespinasse for technical assistance.
| Footnotes |
|---|
Received 3/30/06. Revised 8/ 8/06. Accepted 9/19/06.
| References |
|---|
|
|
|---|
2 chain and regulate epithelial cell migration. Biochem Biophys Res Commun 2003;303:10127.[CrossRef][Medline]
2ß1 integrin-mediated interaction with the laminin 5
2 chain. J Cell Sci 2001;114:81123.[Abstract]
2ß1. J Cell Sci 1998;111:19932004.
3ß1 integrin. APMIS 2000;108:16172.[CrossRef][Medline]
2 chain degradation to mammary epithelial cell migration. J Cell Sci 2001;112:261529.
2 chain and matrix metalloproteinase-2 may trigger colorectal carcinoma invasiveness through formation of budding tumor cells. Anticancer Res 2003;23:41139.[Medline]
2 chains are frequently co-expressed in cancer cells. Pathol Int 2004;54:68892.[CrossRef][Medline]This article has been cited by other articles:
![]() |
N. Garamszegi, S. P. Garamszegi, L. A. Shehadeh, and S. P. Scully Extracellular Matrix-Induced Gene Expression in Human Breast Cancer Cells Mol. Cancer Res., March 1, 2009; 7(3): 319 - 329. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tripathi, S. Nandana, H. Yamashita, R. Ganesan, D. Kirchhofer, and V. Quaranta Laminin-332 Is a Substrate for Hepsin, a Protease Associated with Prostate Cancer Progression J. Biol. Chem., November 7, 2008; 283(45): 30576 - 30584. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |